Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

AMICUS TH Form 4 June 13, 2016		CS INC										
	FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSIO								OMB APPROVAL			
-	UNITE	CD STATES	ITIES AND EXCHANGE C hington, D.C. 20549				COMMISSION	OMB Number:	3235-0287			
Check this if no longe	or							Expires:	January 31, 2005			
subject to Section 16	51A1 .	EMENTO	F CHAN	GES IN BENEFICIAL OWN SECURITIES				NERSHIP OF	Estimated a burden hou	average rs per		
Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed J s Section 1	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							response	0.5		
(Print or Type R	esponses)											
Redmile Group, LLC Symbol				er Name and Ticker or Trading US THERAPEUTICS INC]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
												(Last)(First)(Middle)3. Date of (Month/Date)ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-30006/03/20
(Street) 4. If Am			4. If Ame	endment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mor SAN FRANCISCO, CA 94129				onth/Day/Year)				Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting				
(City)	(State)	(Zip)						Person				
								uired, Disposed of		•		
1.Title of Security (Instr. 3)	2. Transaction 1 (Month/Day/Yo	ear) Executio any		3. Transactic Code (Instr. 8)	4. Securit on(A) or Dis (D) (Instr. 3, 4	sposed	of	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock, Par Value \$0.01	06/03/2016			Code V P	Amount 66,300	(D) A	Price \$ 7.2 (1)	(Instr. 3 and 4) 12,956,446	I	See Footnote (2)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. oriNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
I. S.	Director	10% Owner	Officer	Other		
Redmile Group, LLC ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO, CA 94129		Х				
Green Jeremy C/O REDMILE GROUP, LLC ONE LETTERMAN DRIVE, BLDG D, STE D3-300 SAN FRANCISCO, CA 94129	Х					
Signatures						
Redmile Group, LLC By /s/ Jeremy Green, Managing Member	06/13/2016					
**Signature of Reporting Person		Date				
/s/ Jeremy Green	06/13/2016					
**Signature of Reporting Person		Date				

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This constitutes the weighted average purchase price. The prices range from \$7.17 to \$7.23. The Reporting Persons will provide upon (1) request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of

(2) Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.